The European Commission has granted centralised marketing authorisation for Dexdor (dexmedetomidine), indicated for sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale 0 to -3).
Dexdor (dexmedetomidine) is now licensed across all 27 countries in the European Union.
The active substance of Dexdor is dexmedetomidine, a sedative agent originated by Orion Corporation’s pharmaceutical R&D.
Dexmedetomidine is available with the brand name Precedex in more than 30 countries outside Europe, including the USA (since 2000) and Japan (since 2004).
The distributor for the product outside Europe is Hospira, under Orion’s license.
